Department of Biomedical Informatics, The Ohio State University, Columbus, OH, 43210, USA.
Department of Research Information Technology, College of Medicine, The Ohio State University, Columbus, OH, USA.
BMC Med Inform Decis Mak. 2023 Jul 19;23(1):128. doi: 10.1186/s12911-023-02221-4.
Cardiovascular disease is the leading cause of death in the United States (US). Despite the well-recognized efficacy of statins, statin discontinuation rates remain high. Statin intolerance is a major cause of statin discontinuation. To accurately diagnose statin intolerance, healthcare professionals must distinguish between statin-associated and non-statin-associated muscle symptoms, because many muscle symptoms can be unrelated to statin therapy. Patients' feedback on muscle-related symptoms would help providers make decisions about statin treatment. Given the potential benefits and feasibility of existing apps for cardiovascular disease (CVD) management and the unmet need for an app specifically addressing statin intolerance management, the objectives of the study were 1) to describe the developmental process of a novel app designed for patients who are eligible for statin therapy to lower the risk of CVD; 2) to explore healthcare providers' feedback of the app; and 3) to explore patients' app usage experience.
The app was developed by an interdisciplinary team. Healthcare provider participants and patient participants were recruited in the study. Providers were interviewed to provide their feedback about the app based on screenshots of the app. Patients were interviewed after a 30 days of app usage.
The basic features of the app included symptom logging, vitals tracking, patient education, and push notifications. Overall, both parties provided positive feedback about the app. Areas to be improved mentioned by both parties included: the pain question asked in symptom tracking and the patient education section. Both parties agreed that it was essential to add the trend report of the logged symptoms.
The results indicated that providers were willing to use patient-reported data for disease management and perceived that the app had the potential to facilitate doctor-patient communication. Results also indicated that user engagement is the key to the success of app efficacy. To promote app engagement, app features should be tailored to individual patient's needs and goals. In the future, after it is upgraded, we plan to test the app usability and feasibility among a more diverse sample.
心血管疾病是美国(美国)的主要死亡原因。尽管他汀类药物的疗效得到了广泛认可,但他汀类药物的停药率仍然很高。他汀类药物不耐受是他汀类药物停药的主要原因。为了准确诊断他汀类药物不耐受,医疗保健专业人员必须区分与他汀类药物相关和非与他汀类药物相关的肌肉症状,因为许多肌肉症状与他汀类药物治疗无关。患者对肌肉相关症状的反馈将有助于提供者做出关于他汀类药物治疗的决策。鉴于现有应用程序在心血管疾病(CVD)管理方面的潜在益处和可行性,以及专门针对他汀类药物不耐受管理的应用程序的需求未得到满足,本研究的目的是:1)描述一款专为有资格接受他汀类药物治疗以降低 CVD 风险的患者设计的新型应用程序的开发过程;2)探索医疗保健提供者对该应用程序的反馈;3)探索患者的应用程序使用体验。
该应用程序由一个跨学科团队开发。在研究中招募了医疗保健提供者参与者和患者参与者。根据应用程序的屏幕截图,提供者接受了采访,以提供他们对该应用程序的反馈。患者在使用该应用程序 30 天后接受了采访。
该应用程序的基本功能包括症状记录、生命体征跟踪、患者教育和推送通知。总的来说,双方对该应用程序都给予了积极的反馈。双方提到需要改进的领域包括:症状跟踪中的疼痛问题和患者教育部分。双方都认为添加记录症状的趋势报告至关重要。
结果表明,提供者愿意使用患者报告的数据进行疾病管理,并认为该应用程序有可能促进医患沟通。结果还表明,用户参与是应用程序疗效成功的关键。为了提高应用程序的参与度,应用程序的功能应根据患者的个人需求和目标进行定制。在未来,升级后,我们计划在更多样化的样本中测试该应用程序的可用性和可行性。